Overview: HCV RNA Qualitative PCR TestIntroduction: The HCV RNA Qualitative PCR Test detects hepatitis C viral RNA to confirm infection, causing jaundice or fatigue. Following 2023 AASLD guidelines, it uses PCR for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, confirming active infection, and improving outcomes in virology for patients with suspected hepatitis C, ensuring timely treatment to prevent chronic liver disease.
Other Names: HCV RNA Qual Assay, Hepatitis C PCR Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: HCV RNA testing began in the 1990s with PCR development. Qualitative PCR assays improved in the 2000s, enhancing infection confirmation.
Purpose: Confirms hepatitis C infection, guides antiviral therapy, and detects HCV RNA in patients with jaundice or fatigue.
Test Parameters: 1. HCV RNA (Qualitative)
Pretest Condition: No fasting required. Collect serum, plasma, or saliva at any time. Report symptoms like jaundice, fatigue, or nausea, and list medications or risk factors.
Specimen: 2-5 mL serum (SST), 2-4 mL plasma (EDTA), or 1-2 mL saliva (sterile container). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document jaundice, fatigue, nausea, or history of hepatitis C exposure. Include current medications, risk factors (e.g., IV drug use), and treatment history.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy.
Procedural Considerations: Uses PCR to detect HCV RNA presence. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often following positive anti-HCV results.
Factors Affecting Result Accuracy: Improper sample handling, contamination, or low viral load can affect results. Antiviral therapy may suppress RNA detection.
Clinical Significance: Positive HCV RNA confirms active hepatitis C, prompting antiviral therapy. Negative results may require repeat testing in early infection or low viral load.
Specialist Consultation: Consult a hepatologist or infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: Anti-HCV, HCV genotype, or liver function tests to confirm infection and guide therapy.
Test Limitations: False negatives may occur in early infection or low viral load. Clinical correlation is needed.
References: AASLD Hepatitis C Guidelines, 2023; Hepatology, Ghany MG, 2022.
